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Background. Adherence to antiretroviral therapy (ART) is crucial to preventing mother-to-child transmission of human immu-
nodeﬁciency virus (HIV) and ensuring the long-term effectiveness of ART, yet data are sparse from African routine care programs on
maternal adherence to triple ART.
Methods. We analyzed data from women who started ART at 13 large health facilities in Malawi between September 2011 and
October 2013. We deﬁned adherence as the percentage of days “covered” by pharmacy claims. Adherence of ≥90% was deemed
adequate. We calculated inverse probability of censoring weights to adjust adherence estimates for informative censoring. We
used descriptive statistics, survival analysis, and pooled logistic regression to compare adherence between pregnant and breastfeeding
women eligible for ART under Option B+, and nonpregnant and nonbreastfeeding women who started ART with low CD4 cell
counts or World Health Organization clinical stage 3/4 disease.
Results. Adherence was adequate for 73% of the women during pregnancy, for 66% in the ﬁrst 3 months post partum, and for
about 75% during months 4–21 post partum. About 70% of women who started ART during pregnancy and breastfeeding adhered
adequately during the ﬁrst 2 years of ART, but only about 30% of them had maintained adequate adherence at every visit. Risk factors
for inadequate adherence included starting ART with an Option B+ indication, at a younger age, or at a district hospital or health
center.
Conclusions. One-third of women retained in the Option B+ program adhered inadequately during pregnancy and breastfeed-
ing, especially soon after delivery. Effective interventions to improve adherence among women in this program should be
implemented.
Keywords. adherence; antiretroviral therapy; Option B+; mother-to-child-transmission; HIV.
In 2011, Malawi pioneered a simpliﬁed test and treat policy (Op-
tion B+) to effectively prevent mother-to-child transmission by
providing lifelong antiretroviral therapy (ART) to pregnant and
breastfeeding women infected with human immunodeﬁciency
virus (HIV), regardless of immunological or clinical criteria
[1, 2]. Option B+ was adopted by other low-resource countries
and is now recommended by the World Health Organization
(WHO) [3]. Under Option B+, HIV infection is diagnosed in
many women during routine testing in antenatal care, when
they are asymptomatic, and these women start treatment soon
after that [4]. They receive a daily ﬁxed-dose combination of efa-
virenz, tenofovir, and lamivudine. They collect new medication at
each monthly visit for the ﬁrst 6 months of treatment, and every
2–3 months thereafter [1, 2].
ART uptake greatly improved after Option B+ was implement-
ed [5], but there is concern that women with asymptomatic HIV
infections may not be retained or adhere poorly to treatment [6].
A recent study showed that about 30% of women who started
ART under Option B+ were lost to follow-up (LTF) 3 years
after starting ART, but no study has described adherence
among women in the Option B+ program [7]. A systematic re-
view of studies published before 2012 found that 73% of women
adhered well during pregnancy, but only 53% adhered after de-
livery [8].More recent studies suggest higher levels of adherence,
during both pregnancy and the postpartum period [9–12]. Inad-
equate adherence to ART is associated with loss of viral suppres-
sion, increased risk of transmitting HIV, therapeutic failure, and
viral resistance [13–17].
We examined adherence of women who began treatment be-
tween 1 September 2011 and 15 October 2013, at 13 health
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facilities in Malawi. We compared adherence between pregnant
and breastfeeding women eligible for ART under Option B+, and
women who were not pregnant and not breastfeeding and started
ART with a CD4 cell count <350/µL or with WHO clinical stage
3/4 disease.
METHODS
Study Design and Patient Eligibility
We included HIV-infected women (deﬁned here as ≥15 years
old), who started an ART regimen of efavirenz, tenofovir, and
lamivudine between 1 September 2011 and 15 October 2013
and later returned to care after that (Figure 1). Our data came
from 13 health facilities in Malawi that used electronic medical
records systems (EMRS) during the study period and entered
pharmacy data prospectively at the point of care. At most
study facilities, women started ART in antenatal care and
were referred to ART clinics 6 weeks post partum. Ethical ap-
proval was granted by the Malawi National Health Sciences Re-
search Committee and the Cantonal Ethics Committee of Bern,
Switzerland.
Figure 1. Flow of eligibility of study participants. Abbreviation: ART, antiretroviral therapy.
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Data Sources
Healthcare workers use an EMRS with barcode scanners and
touchscreens to record data at the point of care [18]. Pharmacy
claims are registered with barcode scanners. The EMRS records
type of ART regimen, date of drug dispensation, number of re-
turned pills, and number of pills dispensed. One facility had
viral load data for 498 women (27%), and we compared adher-
ence with viral suppression in this subgroup (Figure 1). Date of
delivery is recorded in paper-based birth registers for HIV-
exposed children and not in maternal ART records. We entered
paper records into a database and used probabilistic record link-
age to merge maternal and infant records. For the subgroup of
women we linked, we compared antepartum and postpartum
adherence (Figure 1).
Outcomes
We deﬁned adherence as the proportion of days “covered” by
pharmacy claims, calculated as the percentage of days drugs
were available to women during a time interval [19]. Adherence
was determined for each interval between clinic visits and for
ﬁxed time intervals (3 months and 2 years). In a subset of
women (Figure 1), we compared virological suppression be-
tween women with different adherence levels and then deﬁned
a threshold for adequate adherence. Adherence of ≥90% was
categorized “adequate” and adherence of <90% as “inadequate.”
Virological suppression was deﬁned as viral load value of <400
copies/mL, measured ≥6 months after start of ART. Timing of
viral load testing was not standardized. We only considered re-
sults of viral load tests taken at least 6 months after ART
initiation.
Procedures
We classiﬁed women by pregnancy and breastfeeding status at
the start of ART: pregnant and eligible for ART under Option
B+, breastfeeding and eligible for ART under Option B+, or not
pregnant or breastfeeding and eligible for ART owing to WHO
stage 3 or 4 disease or CD4 cell count <350/µL. Women were
considered “retained in care” between the start of ART and
their last drug reﬁll. We classiﬁed women >60 days late for
drug reﬁlls by the end of the study as LTF. Women who trans-
ferred to another facility were classiﬁed as “transferred out,” and
those who informed healthcare workers that they had discontin-
ued ART were classiﬁed as “stopped ART.”
Statistical Analysis
We calculate adjusted odds ratios (aORs) with 95% conﬁdence
intervals (CIs) for virological suppression by adherence strata
(<80%, 80%–89%, 90%–99%, or 100%) to validate our
adherence measure and determine the threshold for adequate
adherence. We therefore used multivariable logistic regression
adjusted for age, pregnancy and breastfeeding status at start of
ART, and time receiving ART before viral load test.
We followed up women for a maximum of 2 years with ART.
Women who stopped ART, died, were LTF, or transferred out
were censored on the day they submitted their last pharmacy
claim. In an earlier analysis of data from the same cohort of
women, we showed that censoring did not occur at random:
women with poor adherence had higher dropout rates than
those with good adherence [7]. This mechanism of “informative
censoring” biases analysis of patterns of adherence over time
[20]. We used stabilized inverse probability of censoring weight-
ing (IPCW) to adjust for informative censoring. Weights were
calculated as the inverse of the probability of being under fol-
low-up, given observed adherence (<80%, 80%–89%, 90%–
99%, or 100%), pregnancy and breastfeeding status at start of
ART, age (15–19, 20–24, 25–29, or ≥30 years), WHO clinical
stage at start of ART, and facility type (health center, district
hospital, faith-based hospital, or central hospital).
We used descriptive statistics to examine the characteristics of
women at start of ART. We used Fine and Gray’s method to es-
timate cumulative incidences of LTF, transferring out, death,
and stopping ART [21]. Mortality, transferring out, stopping
ART, and LTF were competing events. We used the Kaplan–
Meier method to estimate retention in care and the probability
that women would maintain adequate adherence. We split fol-
low-up time into 3-month intervals and determined the pro-
portions of women with adherence ≥90% or <90% in each
interval. For the subset of women who could be linked to infants
(Figure 1), we determined proportions of women with adher-
ence ≥90% or <90% during pregnancy and in 3-month intervals
post partum. We used pooled logistic regression with cluster-
based robust standard errors to calculate adjusted hazard ratios
(aHRs) for adequate adherence. Analysis was adjusted for age,
pregnancy and breastfeeding status at the start of ART, facility
type, and WHO clinical stage. We used Stata software, version
14, for all statistical analyses.
RESULTS
Characteristics of Study Participants
A total of 7467 women met our eligibility criteria: 4248 (57%)
were pregnant, 1614 (22%) were breastfeeding, and 1605 (22%)
were neither pregnant nor breastfeeding at the start of ART
(Figure 1; Table 1). Pregnant and breastfeeding women started
ART younger and had less advanced HIV disease than women
who were not pregnant or breastfeeding.
Adherence and Virological Suppression
One facility had viral load data, and we compared adherence
with virological suppression in this subgroup. Out of 1841
women included in the study facility, 498 (279 Option B+
women) were eligible for this analysis (Figure 1). The median
time between ART initiation and the viral load test was 504
days (interquartile range, 259–743). Of tested patients, 448
(90.0%) were virologically suppressed. Women whose adher-
ence between start of ART and the viral load test was <90%
were much less likely to be virologically suppressed than
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those whose adherence was 100% (aOR for adherence <80%,
0.15 [95% CI, .06–.38]; aOR for adherence 80%–89%, 0.37
[.14–.95]). Women whose adherence was 90%–99% had a sim-
ilar chance of virological suppression (aOR, 0.96; 95% CI, .43–
2.17) compared with those with 100% adherence. Based on
these results, we considered <90% adherence inadequate and
≥90% adequate.
Adherence Among Women Retained in Care
Kaplan–Meier estimates for retention after 2 years by pregnancy
and breastfeeding status at ART initiation were 59.4% (95% CI,
57.9%–60.1%) for pregnant women, 65.2% (62.9%–67.5%) for
breastfeeding women, and 68.0% (65.7%–70.3%) for women
who were not pregnant or breastfeeding. The cumulative inci-
dence of LTF by year 2 was 24.5% (95% CI, 23.2%–25.8%)
among women who started ART during pregnancy, 20.2%
(95% CI, 18.3%–22.2%) among those who started ART while
breastfeeding, and 17.0% (95% CI, 15.2%–18.8%) among
those who were neither pregnant nor breastfeeding when they
started treatment. About 15% of the women from all groups
transferred out, <1% stopped ART, and <1% died.
Among women retained after 2 years, adequate adherence
(≥90%) during the ﬁrst 2 years of ART was 67.0% (95% CI,
65.1%–68.8%) for women who started ART during pregnan-
cy, 72.9% (70.1%–75.6%) for those who started ART while
breastfeeding, and 78.1% (75.6%–80.7%) for women who were
neither pregnant nor breastfeeding. The probability of main-
taining adequate adherence at every follow-up visit during the
ﬁrst 2 years on ART was 0.25 (95% CI, .24–.27) in women who
started ART during pregnancy, 0.30 (.28–.33) in those who
started ART while breastfeeding, and 0.46 (.44–.49) in women
those were neither pregnant nor breastfeeding (Figure 2).
Adherence Pattern Over Time on ART
Figure 3 shows observed and IPCW-adjusted adherence esti-
mates for 3-month intervals after ART initiation. Observed
data (Figure 3A and 3B) show proportions of women with ad-
equate and inadequate adherence among women retained in
care by the end of the time interval. The proportion of ade-
quately adhering women who started ART during pregnancy
dropped from 71.1% (95% CI, 69.7%–72.5%) during the ﬁrst
3 months of ART to 64.9% (63.3%–66.5%) during months 4–
6. Thereafter, the proportion of women who adhered adequately
increased to 79.3% (77.7%–80.9%) (Figure 3A). Among women
who started ART while breastfeeding, between 75.0% (95% CI,
72.7%–77.3%) and 79.8% (95% CI, 77.4%–82.2%) adhered ad-
equately (Figure 3B). Between 80.8% (95% CI, 78.7%–82.9%)
and 86.3% (84.2%–88.4%) of women who started ART when
they were neither pregnant nor breastfeeding adhered adequate-
ly (Supplementary Appendix 1).
Table 1. Women’s Characteristics at Start of Antiretroviral Therapy
Characteristic
Women by Pregnancy and Breastfeeding Status at Start of ART, No. (%)a
Pregnant (Option B+)
(n = 4248; 56.9%)
Breastfeeding (Option B+)
(n = 1614; 21.6%)
Not Pregnant or Breastfeeding
(n = 1605; 21.5%)
Total (n = 7467;
100.0%)
Age group
15–19 y 279 (6.6) 79 (4.9) 48 (3.0) 406 (5.4)
20–24 y 958 (22.6) 360 (22.3) 169 (10.5) 1487 (19.9)
25–29 y 1731 (40.7) 646 (40.0) 424 (26.4) 2801 (37.5)
≥30 y 1280 (30.1) 529 (32.8) 964 (60.1) 2773 (37.1)
Age, median (IQR), y 28 (24–32) 28 (24–32) 33 (27–39) 29 (24–33)
Year of ART initiation
2011 516 (12.1) 495 (30.7) 248 (15.5) 1259 (16.9)
2012 2236 (52.6) 803 (49.8) 475 (29.6) 3514 (47.1)
2013 1496 (35.2) 316 (19.6) 882 (55.0) 2694 (36.1)
WHO clinical stage
1 4187 (98.6) 1435 (88.9) 369 (23.0) 5991 (80.2)
2 38 (0.9) 87 (5.4) 169 (10.5) 294 (3.9)
3 15 (0.4) 1 (0.1) 749 (46.7) 765 (10.2)
4 8 (0.2) 0 (0.0) 206 (12.8) 214 (2.9)
Unknown 0 (0.0) 91 (5.6) 112 (7.0) 203 (2.7)
Facility type
Central hospital 462 (10.9) 180 (11.2) 464 (28.9) 1106 (14.8)
District hospital 2546 (59.9) 858 (53.2) 723 (45.0) 4127 (55.3)
Mission hospital 349 (8.2) 267 (16.5) 180 (11.2) 796 (10.7)
Health center 891 (21.0) 309 (19.1) 238 (14.8) 1438 (19.3)
Abbreviations: ART, antiretroviral therapy; IQR, interquartile range; WHO, World Health Organization.
a Data represent No. (%) of women unless otherwise indicated.
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IPCW-adjusted estimates (Figure 3C and 3D) are adjusted for
censoring. After adjustment, adherence among women who
started ART during pregnancy was constant over time, except
during months 4–6, when it was signiﬁcantly lower (Figure 3C).
In women who started ART while breastfeeding, adherence re-
mained constant over time (Figure 3D), and in women who
were not pregnant or breastfeeding, adherence dropped after
the ﬁrst 3 months and remained constant thereafter (Supple-
mentary Appendix 1).
Adherence Before and After Delivery
We linked maternal and infant records to determine the date of
delivery in 916 (22%) of the 4248 women who started ART dur-
ing pregnancy. Of those women, 765 were eligible for analysis
(Figure 1) in which we compared adherence before and after de-
livery. Women who could be linked to their infants had higher
mean adherence during the ﬁrst 2 years of ART than those who
could not be linked (89.8% vs 87.1%; P = .002). The populations
also differed as to year of ART initiation and facility type (Sup-
plementary Appendix 2). The median time from start of ART to
delivery was 3.6 months. IPCW-adjusted analysis showed that,
during pregnancy, 72.5% (95% CI, 69.2%–75.5%) of the women
adhered adequately. In the ﬁrst 3 months after delivery, the pro-
portion of women with adequate adherence dropped to 65.8%
(95% CI, 62.2%–69.2%). In the 6 subsequent 3-month intervals
(months 4–21 post partum), the proportion of women with ad-
equate adherencewas similar to that during pregnancy (Figure 4).
Risk Factors for Inadequate Adherence
Women who started ART during pregnancy (aHR, 1.66; 95%
CI, 1.43–1.93) or while breastfeeding (1.45, 1.24–1.70) were
more likely to adhere inadequately (<90%) in the ﬁrst 2 years
of ART than women who were not pregnant or breastfeeding
when they started ART. Women aged 15–19 years (aHR, 1.78;
95% CI, 1.51–2.11), 19–24 years (1.47; 1.32–1.63), or 25–29
years (1.12; 1.03–1.22) were more likely to adhere inadequately
than those aged ≥30 or older. Women managed in district hos-
pitals (aHR, 2.37; 95% CI, 2.06–2.72) and urban health centers
(2.20; 1.89–2.56) were at higher risk of inadequate adherence
than those managed in faith-based health facilities (1.21;
1.02–1.44) or central hospitals (reference). Women in WHO
clinical stage 3 were more likely to adhere inadequately (aHR,
1.63; 95% CI, 1.23–2.16) than those in WHO clinical stage 1
(1.18; 0.89–1.56), 2 (1.02; 0.72–1.43), or 4 (reference).
DISCUSSION
About 70% of the Option B+ patients retained after 2 years ad-
hered adequately (≥90%), but only about a third of women
maintained adequate adherence at every visit during the ﬁrst
2 years of ART. Women who started ART under Option B+
were about 1.5 times more likely to adhere inadequately than
those who were not pregnant or breastfeeding. Other risk fac-
tors for inadequate adherence were younger age and receiving
care at district hospitals or health centers. We examined adher-
ence during and after pregnancy in a subgroup of women and
found it to be constant during pregnancy and breastfeeding;
slightly more than 70% of these women adhered adequately, ex-
cept during the ﬁrst 3 months post partum, when fewer women
adhered. In a subgroup analysis, we showed that women who
adhered adequately were much more likely to be virologically
suppressed than those who adhered inadequately.
Based on pharmacy records, we compared adherence to ART
for a large group of women enrolled in Malawi’s Option B+ pro-
gram. We validated our adherence measure and determined the
threshold for adequate adherence against virological outcomes
[22]. The ≥90% threshold aligns with a recent systematic review
that found a threshold of slightly lower than 95% predicted vi-
rological suppression [23]. Pharmacy-based adherence indica-
tors are widely used and considered superior to self-reported
data, because self-reports are subject to recall and social desir-
ability bias [22]. Pharmacy-based adherence measures do have
limitations and may be biased: adherence may be overestimated
in patients who do not take all the pills they collect. Adherence
will be underestimated if patients received drugs from other
sources or without documentation [24].
To minimize the risk of incorrectly documented drug dispen-
sation, healthcare workers used barcode scanners and recorded
drug dispensation prospectively at the point of care [18], except
during occasional outages of the electronic system, when data
were collected on paper forms and entered into the system ret-
rospectively. Data entry may not always have been complete, but
it is unlikely that we seriously underestimated adherence be-
cause retrospective data entry was rare. Our earlier analysis of
data from the same cohort revealed that women with poor ad-
herence have a higher risk of LTF [7].We used IPCW to adjust
for informative censoring and enable a valid comparison of an-
tepartum and postpartum adherence [25, 26]. The date of
Figure 2. Probability of maintaining adequate adherence (≥90%) at every clinic
visit (lines) and 95% confidence intervals (shaded areas) compared according to
pregnancy and breastfeeding status at the start of antiretroviral therapy (ART).
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delivery was not recorded in maternal ART records, so we could
not calculate antepartum and postpartum adherence for all
women. By linking maternal and infant records, we determined
date of delivery for about 20% of the women. This subset was
Figure 3. Adherence during 3-month intervals after antiretroviral therapy (ART) initiation. Adherence is compared according to pregnancy and breastfeeding status at start of
ART: pregnant (A, C) or breastfeeding (B, D). Observed and inverse probability of censoring weighted (IPCW) estimates are shown for adherence levels during 3-month intervals
after ART initiation. Data represent percentages (with 95% confidence intervals) of women with adherence of <90% or ≥90%. Observed data include women retained in care
by the end of the interval. IPCW-adjusted data represent a pseudopopulation that would have been observed without censoring.
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not representative of all women who started ART during preg-
nancy; those in the subset had slightly better adherence, prob-
ably because women who adhere to ART are more likely to
enroll their infants in care. Adherence levels for the antepartum
and postpartum period may therefore be slightly overestimated.
A meta-analysis of studies published before 2012 compared
maternal antepartum and postpartum adherence and found
poor and deteriorating adherence after delivery [8].More recent
data suggest high and constant levels of adherence during preg-
nancy and breastfeeding. The PROMOTE trial and the Kisumu
Breastfeeding Study included pregnant women regardless of
clinical or immunological criteria. In the PROMOTE trial,
mean self-reported adherence in the antepartum and postpar-
tum period was >97% [10]. In the Kisumu Breastfeeding
Study, about 80% of women had >95% adherence during preg-
nancy and breastfeeding [12]. Two cohort studies from Africa
included pregnant women with a low CD4 cell count or at an
advanced clinical stage, and reported adherence was high dur-
ing and after pregnancy [9, 11]. In general, our data are in line
with these studies, but comparisons are limited by heterogeneous
study designs, eligibility criteria, and adherence measures. We
found overall adherence levels to be constant during pregnancy
and breastfeeding but noted a drop in adherence in the ﬁrst 3
months after delivery. Out-referral after delivery, postnatal de-
pression, or difﬁculties travelling to the facilities after delivery
may explain the temporary decline in adherence [27, 28].
Medical sociologists argue that patients may interrupt treat-
ment or reduce doses to test the effectiveness of medication and
discontinue treatment if they think it is ineffective [29, 30]. Pa-
tients’ state of health before they start therapy and adverse ef-
fects of drugs can inﬂuence patient assessment of treatment
effectiveness. Patients who feel sick before starting ART feel bet-
ter quickly after they start treatment [30, 31]. However, patients
who feel well before starting ART may see no improvement in
their own health or may experience unpleasant adverse effects
[30, 32]. Pregnant and breastfeeding women started ART in a
less advanced stage of HIV infection than women who were
not pregnant or breastfeeding, which may explain their worse
Figure 4. Adherence before and after delivery. Observed (A) and inverse probability of censoring weighted (IPCW) (B) estimates are shown; data represent percentages (95%
confidence intervals) of women with adherence of <90% or ≥90% during pregnancy and in 3-month intervals after delivery. IPCW-adjusted estimates are adjusted for cen-
soring, representing a pseudopopulation that would have been observed without censoring. Data are from 765 women who started antiretroviral therapy (ART) during pregnancy
and could be linked to infant records (see Figure 1).
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adherence. This hypothesis is supported by a qualitative study
showing that feeling healthy and adverse effects are reasons why
Option B+ women stop taking their medication [33] and by
quantitative studies showing that high CD4 cell counts are as-
sociated with treatment interruptions or defaulting [34, 35]. We
examined the association between clinical staging and adher-
ence and found no support for the hypothesis that starting at
an advanced clinical stage leads to better adherence. Inaccurate
WHO staging in routine care may explain our unexpected
ﬁnding.
About a quarter of the women who started ART with an Op-
tion B+ indication were LTF during the ﬁrst 2 years of ART [7].
About 30% of those retained adhered inadequately. HIV-infected
patients with inadequate adherence are at a high risk of viral re-
bound and drug resistance [13, 17, 36]. Programs should care-
fully monitor drug resistance and the long-term effectiveness of
ART among women who started ART under Option B+ and
should expect demand for second-line ART to increase in this
population. If access to viral load count is limited, it may be use-
ful to target testing to patients with poor adherence. Pharmacy-
based or self-reported adherence measures could identify
patients with adherence problems [22, 37]. Programs should
consider implementing feasible, evidence-based interventions
to promote adherence, including adherence clubs, adherence
counseling, short message service text message reminders, and
treatment supporters, and could also consider better-tolerated
ﬁrst-line options [38–40].
Most women enrolled in the Option B+ program adhered
well during pregnancy and breastfeeding, but close to one-
third adhered inadequately. We suggest that long-term virolog-
ical outcomes be closely monitored and effective interventions
be deployed to improve adherence and retention among preg-
nant and breastfeeding women.
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Supplementary materials are available at http://cid.oxfordjournals.org.
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